+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Inotek Pharma - logo

Inotek Pharma - Company & Market Research Reports

Following a company allows Research and Markets to customize your experience and provide personalized recommendations.

Inotek Pharmaceuticals is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts. It is focused on the development and commercialization of therapies for glaucoma and other serious diseases of the eye. The company's lead product candidate is Trabodenoson, formerly known as INO-8875, which is in Phase III clinical trials for lowering IOP. Trabodenoson has completed Phase 1, 2, and 3 clinical trials in subjects with OHT and POAG. Inotek was founded in 1999.

From
From
Open-Angle Glaucoma - Pipeline Insight, 2019 - Product Thumbnail Image

Open-Angle Glaucoma - Pipeline Insight, 2019

  • Drug Pipelines
  • 70 Pages
From
From
From
From
From
From
From
From
From
From
Glaucoma Global Clinical Trials Review, H2, 2017 - Product Thumbnail Image

Glaucoma Global Clinical Trials Review, H2, 2017

  • Clinical Trials
  • 586 Pages
From
From
Loading Indicator
adroll